Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441

Stopped Based on results from the pilot phase, the study is terminated. No safety events leading to discontinuation were reported

Conditions

• Healthy Subjects

Interventions

• DRUG: ACT-334441 2 mg
• DRUG: ACT-334441 4 mg
• DRUG: Placebo
• DRUG: Atenolol
• DRUG: Diltiazem ER

Sponsor

Viatris Innovation GmbH